Related Experiment Video

Updated: May 3, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

798

Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease

Cláudia Nogueira1, Selma B Souto2, Eduardo Vinha3

  • 1Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Sāo Joāo, Faculty of Medicine, University of Porto, Porto, Portugal.

Hormones (Athens, Greece)
|January 25, 2014
PubMed

Insights

Managing type 2 diabetes in patients with chronic kidney disease (CKD) is complex. This review examines oral glucose-lowering drugs, focusing on their pharmacokinetics, metabolism, and safety in T2DM patients with CKD.

Area of Science:

  • Nephrology
  • Endocrinology
  • Clinical Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management is complicated by chronic kidney disease (CKD).
  • Renal impairment impacts drug pharmacokinetics, potentially leading to toxicity, drug interactions, or ineffective treatment.
  • Limited therapeutic options exist for T2DM patients with moderate to severe CKD.

Purpose of the Study:

  • To review the pharmacokinetics, metabolism, and safety of oral glucose-lowering drugs.
  • To evaluate therapeutic options for T2DM patients with varying degrees of CKD.

Main Methods:

  • Literature review of pharmacokinetic and safety data.
  • Analysis of oral glucose-lowering drug profiles in T2DM patients with CKD.

Main Results:

  • Oral glucose-lowering drugs have diverse pharmacokinetic profiles and safety considerations in CKD.
  • Drug clearance and metabolism are significantly altered in patients with renal impairment.
  • Therapeutic strategies require careful selection based on CKD severity.

Conclusions:

  • Understanding drug pharmacokinetics and safety is crucial for effective T2DM management in CKD patients.
  • Individualized treatment approaches are necessary due to altered drug disposition in renal impairment.
  • Further research is needed to expand safe and effective oral therapeutic options for T2DM with CKD.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K